287 related articles for article (PubMed ID: 20452466)
1. The point on the ongoing B-cell depleting trials currently in progress over the world in primary Sjögren's syndrome.
Saraux A
Autoimmun Rev; 2010 Jul; 9(9):609-14. PubMed ID: 20452466
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of rituximab treatment in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled trial.
Meijer JM; Meiners PM; Vissink A; Spijkervet FK; Abdulahad W; Kamminga N; Brouwer E; Kallenberg CG; Bootsma H
Arthritis Rheum; 2010 Apr; 62(4):960-8. PubMed ID: 20131246
[TBL] [Abstract][Full Text] [Related]
3. Persistence of immunoglobulin-producing cells in parotid salivary glands of patients with primary Sjögren's syndrome after B cell depletion therapy.
Hamza N; Bootsma H; Yuvaraj S; Spijkervet FK; Haacke EA; Pollard RP; Visser A; Vissink A; Kallenberg CG; Kroese FG; Bos NA
Ann Rheum Dis; 2012 Nov; 71(11):1881-7. PubMed ID: 22615459
[TBL] [Abstract][Full Text] [Related]
4. Reduction of fatigue in Sjögren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study.
Dass S; Bowman SJ; Vital EM; Ikeda K; Pease CT; Hamburger J; Richards A; Rauz S; Emery P
Ann Rheum Dis; 2008 Nov; 67(11):1541-4. PubMed ID: 18276741
[TBL] [Abstract][Full Text] [Related]
5. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome.
Seror R; Sordet C; Guillevin L; Hachulla E; Masson C; Ittah M; Candon S; Le Guern V; Aouba A; Sibilia J; Gottenberg JE; Mariette X
Ann Rheum Dis; 2007 Mar; 66(3):351-7. PubMed ID: 16950808
[TBL] [Abstract][Full Text] [Related]
6. Anti-CD20 treatment in primary Sjögren's syndrome.
Isaksen K; Jonsson R; Omdal R
Scand J Immunol; 2008 Dec; 68(6):554-64. PubMed ID: 19000095
[TBL] [Abstract][Full Text] [Related]
7. Rituximab therapy in primary Sjögren's syndrome.
Alcântara C; Gomes MJ; Ferreira C
Ann N Y Acad Sci; 2009 Sep; 1173():701-5. PubMed ID: 19758218
[TBL] [Abstract][Full Text] [Related]
8. The TRACTISS protocol: a randomised double blind placebo controlled clinical trial of anti-B-cell therapy in patients with primary Sjögren's Syndrome.
Brown S; Navarro Coy N; Pitzalis C; Emery P; Pavitt S; Gray J; Hulme C; Hall F; Busch R; Smith P; Dawson L; Bombardieri M; Wan-Fai N; Pease C; Price E; Sutcliffe N; Woods C; Ruddock S; Everett C; Reynolds C; Skinner E; Poveda-Gallego A; Rout J; Macleod I; Rauz S; Bowman S;
BMC Musculoskelet Disord; 2014 Jan; 15():21. PubMed ID: 24438039
[TBL] [Abstract][Full Text] [Related]
9. Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study.
Steinfeld SD; Tant L; Burmester GR; Teoh NK; Wegener WA; Goldenberg DM; Pradier O
Arthritis Res Ther; 2006; 8(4):R129. PubMed ID: 16859536
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of rituximab in systemic manifestations of primary Sjogren's syndrome: results in 78 patients of the AutoImmune and Rituximab registry.
Gottenberg JE; Cinquetti G; Larroche C; Combe B; Hachulla E; Meyer O; Pertuiset E; Kaplanski G; Chiche L; Berthelot JM; Gombert B; Goupille P; Marcelli C; Feuillet S; Leone J; Sibilia J; Zarnitsky C; Carli P; Rist S; Gaudin P; Salliot C; Piperno M; Deplas A; Breban M; Lequerre T; Richette P; Ghiringhelli C; Hamidou M; Ravaud P; Mariette X;
Ann Rheum Dis; 2013 Jun; 72(6):1026-31. PubMed ID: 23264337
[TBL] [Abstract][Full Text] [Related]
11. Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study.
Pijpe J; van Imhoff GW; Spijkervet FK; Roodenburg JL; Wolbink GJ; Mansour K; Vissink A; Kallenberg CG; Bootsma H
Arthritis Rheum; 2005 Sep; 52(9):2740-50. PubMed ID: 16142737
[TBL] [Abstract][Full Text] [Related]
12. Inefficacy of infliximab in primary Sjögren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjögren's Syndrome (TRIPSS).
Mariette X; Ravaud P; Steinfeld S; Baron G; Goetz J; Hachulla E; Combe B; Puéchal X; Pennec Y; Sauvezie B; Perdriger A; Hayem G; Janin A; Sibilia J
Arthritis Rheum; 2004 Apr; 50(4):1270-6. PubMed ID: 15077311
[TBL] [Abstract][Full Text] [Related]
13. Rituximab in primary Sjögren's syndrome: a ten-year journey.
Carubbi F; Alunno A; Cipriani P; Bartoloni E; Ciccia F; Triolo G; Gerli R; Giacomelli R
Lupus; 2014 Nov; 23(13):1337-49. PubMed ID: 25096066
[TBL] [Abstract][Full Text] [Related]
14. Treatment of primary Sjögren's syndrome with anti-CD20 therapy (rituximab). A feasible approach or just a starting point?
Meiners PM; Vissink A; Kallenberg CG; Kroese FG; Bootsma H
Expert Opin Biol Ther; 2011 Oct; 11(10):1381-94. PubMed ID: 21819314
[TBL] [Abstract][Full Text] [Related]
15. Anti-CD20 antibody in primary Sjögren's syndrome management.
Chen S; Liu Y; Shi G
Curr Pharm Biotechnol; 2014; 15(6):535-41. PubMed ID: 25213362
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: a prospective, multi-center, follow-up study.
Carubbi F; Cipriani P; Marrelli A; Benedetto P; Ruscitti P; Berardicurti O; Pantano I; Liakouli V; Alvaro S; Alunno A; Manzo A; Ciccia F; Gerli R; Triolo G; Giacomelli R
Arthritis Res Ther; 2013 Oct; 15(5):R172. PubMed ID: 24286296
[TBL] [Abstract][Full Text] [Related]
17. BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjögren's syndrome.
Pers JO; Devauchelle V; Daridon C; Bendaoud B; Le Berre R; Bordron A; Hutin P; Renaudineau Y; Dueymes M; Loisel S; Berthou C; Saraux A; Youinou P
Arthritis Rheum; 2007 May; 56(5):1464-77. PubMed ID: 17469105
[TBL] [Abstract][Full Text] [Related]
18. Immune regulation and B-cell depletion therapy in patients with primary Sjögren's syndrome.
Abdulahad WH; Kroese FG; Vissink A; Bootsma H
J Autoimmun; 2012 Aug; 39(1-2):103-11. PubMed ID: 22341852
[TBL] [Abstract][Full Text] [Related]
19. A pilot study to test the efficacy of oral administration of interferon-alpha lozenges to patients with Sjögren's syndrome.
Khurshudian AV
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2003 Jan; 95(1):38-44. PubMed ID: 12539025
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic potential for B-cell modulation in Sjögren's syndrome.
Mariette X
Rheum Dis Clin North Am; 2008 Nov; 34(4):1025-33, x. PubMed ID: 18984420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]